OTCMKTS:GMXAY GENMAB A/S/S (GMXAY) Stock Price, News & Analysis → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Free GMXAY Stock Alerts $30.63 -0.20 (-0.65%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$30.11▼$30.6350-Day Range$26.43▼$31.6852-Week Range$12.10▼$19.00Volume319,427 shsAverage Volume48,553 shsMarket CapitalizationN/AP/E Ratio11.76Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get GENMAB A/S/S alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About GENMAB A/S/S Stock (OTCMKTS:GMXAY)Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.Read More GMXAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMXAY Stock News HeadlinesMarch 18, 2024 | msn.comRetirement Planning: Nearly Half of Gen X and Younger Generations Fear Savings Not Enough — 4 Reasons It’s Never Too Late To Catch UpMarch 17, 2024 | msn.comGemini: Your finance horoscope - March 17March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 16, 2024 | msn.comBMW's annual automotive margin falls below expectationsMarch 15, 2024 | msn.comMG Excelor EV nameplate trademarked, will be brand's 3rd EV after ZS EV & CometMarch 13, 2024 | msn.comAbu Dhabi Launches MGX: A Global Tech VentureFebruary 22, 2024 | bizjournals.comMany managers have a Gen Z problem. Here's how they can solve it.February 22, 2024 | bizjournals.comGen Z is reshaping the workforce. Here's how managers can embrace that change.March 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! February 2, 2024 | msn.comFORD EXPLORER ST DRAGS ACURA MDX TYPE S AND GENESIS GV80 WITH SURPRISING RESULTSJanuary 4, 2024 | msn.comGen Zers are balking at the suggestion that a $74,000 salary is considered 'middle class,' with home ownership feeling like a distant dreamAugust 26, 2023 | usatoday.comGet early Labor Day savings of up to $830 on the Samsung Galaxy Tab S9August 25, 2023 | yahoo.comThis Samsung Galaxy phone packs a killer camera — and it's almost 40% off, today onlyMay 9, 2023 | msn.comEarnings Preview For GenmabFebruary 21, 2023 | benzinga.comEarnings Outlook For GenmabNovember 9, 2022 | technews.tmcnet.comGenmab Announces Financial Results for the First Nine Months of 2022September 21, 2022 | yahoo.comBeReal Is Gen Z’s Fave New Social App That Hollywood Can’t Crack – But Paramount Is Taking a StabSeptember 18, 2022 | msn.comBMW's Farfus forced to skip Autopolis SUPER GT roundSeptember 18, 2022 | msn.comRussia’s secret gem sales are dividing the diamond world — from Mumbai to New YorkSeptember 18, 2022 | msn.comFortnite’s new season adds Spider-Gwen and goopy chromeSeptember 17, 2022 | yahoo.comWatch BMW’s All-Electric, Off-Roading ‘Dune Taxi’ Make Mincemeat of the Arabian DesertSeptember 16, 2022 | msn.com2024 BMW M5 Unofficial Renderings Preview Sedan’s Revamped StylingSeptember 15, 2022 | msn.comThis is the most materialistic generation today — here’s what you should knowSeptember 15, 2022 | msn.comBMW's Upcoming Gen6 Battery Tech To Offer 620 Miles Of RangeSeptember 14, 2022 | msn.comO.T. Genasis is back with new single "I Know You Feel A Way"September 14, 2022 | yahoo.comThis New Restomod Is a Tribute to the Ferraris of the ‘Magnum P.I.’ EraSeptember 14, 2022 | msn.comWhy Geno Smith’s second chance means so muchSee More Headlines Receive GMXAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENMAB A/S/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GMXAY CUSIPN/A CIKN/A Webwww.genmab.com Phone45 70 20 27 28FaxN/AEmployees377Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio11.76 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Jan G. J. van de Winkel (Age 58)Co-Founder, Pres & CEO Mr. David A. Eatwell (Age 58)Exec. VP & CFO Mr. Peter Storm Kristensen (Age 44)Associate Director of Legal & Non-Independent Director Mr. Rick Hibbert (Age 39)Associate Director of Protein Production & Chemistry and Non-Independent Director Dr. Judith V. Klimovsky (Age 61)Exec. VP & Chief Devel. Officer Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors GMXAY Stock Analysis - Frequently Asked Questions How have GMXAY shares performed in 2024? GENMAB A/S/S's stock was trading at $31.84 at the start of the year. Since then, GMXAY stock has decreased by 3.8% and is now trading at $30.63. View the best growth stocks for 2024 here. How do I buy shares of GENMAB A/S/S? Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GMXAY) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENMAB A/S/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.